This excerpt taken from the SNY 6-K filed Jan 30, 2006.
Amaryl® has been facing competition from generics in the United States, resulting in a fall of 28.6% in net sales of the product during the period (with US sales down 86.2%) . An authorized generic version of Amaryl® was launched by Prasco Laboratories at the start of the fourth quarter, and accounted for 29.6% of glimepiride prescriptions in December 2005.
This excerpt taken from the SNY 6-K filed Nov 8, 2005.
Third-quarter net sales of Amaryl® were €195 million, up 19.6% . Net sales rose by 33.6% in the United States (to €63 million), and by 10.0% in Europe (to €68 million).
In the 9 months to end September, net sales of Amaryl® advanced by 18.9% in the United States (to €172 million). In Europe, the product achieved growth of 11.1%, to €195 million. In early October, Prasco Laboratories launched an authorized generic of Amaryl® in the United States.